The published BELIEVE trial tested bimagrumab with semaglutide. The results sharpen the body-composition question while leaving strength, long-term safety and durability unresolved.
The guide now includes knee-pain, patient-reported function and safety findings from the November 8 report. Read those results alongside the earlier weight-loss trials and the sponsor-reported diabetes comparison.
The Lancet report is now published. Read the dose-specific uncertainty and separate combination safety findings, alongside the limits of body-composition measurements.